The EV-HIV Assay, a Point-of-Care Lateral Flow Immunoassay to Accurately Identify HIV Infection from Blood-Based Extracellular Vesicles
The EV-HIV Assay, a Point-of-Care Lateral Flow Immunoassay to Accurately Identify HIV Infection from Blood-Based Extracellular Vesicles
批准号:
10927088
负责人:
KIMBERLY LUKE
金额:
$30.62万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-01 至 2024-08-31
关键词:
AddressBiological AssayBloodContractsDevelopmentDiagnosticDiagnostic testsGoalsHIVHIV InfectionsHuman immunodeficiency virus testImmunoassayLaboratoriesLateralNucleic AcidsSensitivity and SpecificitySepsisSerologyTestingVaccinesclinical practiceextracellular vesiclesnext generationpoint of careprogramsself testingseropositive
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity: The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced seropositivity (VISP), with high sensitivity and specificity. These next generation assays should be developed to address one or all applications/indications of HIV tests, namely: (1) laboratory based tests; ((2) point-of-care and clinical practices; and (3) self-testing. This contract aims to develop a blood-based, lateral flow HIV diagnostic test that can be employed as point-of-care and as well as for self-testing to differentiate between HIV infection from (VISP).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The IRIS-HIV assay, a point-of-care, multiplex serological assay to identify HIV Infection and Vaccine-Induced Seropositivity
-
批准号:10667353
-
项目类别:
-
资助金额:$29.99万
-
财政年份:2022
-
负责人:KIMBERLY LUKE
-
依托单位:
海外基金